VETOQUINOL (VETO) AI Stock Analysis

• Market Cap: €925.99M
• Dividend Yield: 1.06%
• Average Volume (3M): 5.40K
• Price to Earnings (P/E): 17.3
• Beta (1Y): 0.48
• Revenue Growth: -0.95%
• EPS Growth: 27.67%
• Country: FR
• Employees: 2,519
• Sector: General
• Sector Strength: N/A
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 2.69
• Shares Outstanding: 11,881,902
• 10 Day Avg. Volume: 4,099
• 30 Day Avg. Volume: 5,401
• PEG Ratio: 2.53
• Price to Book (P/B): 1.53
• Price to Sales (P/S): 1.64
• P/FCF Ratio: 12.96
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €110.00
• Price Target Upside: 30.33% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 5.33
• Revenue Forecast (FY): €535.70M

• Rating: 72 Outperform
• Price Target: €96.00 ▲(13.74% Upside)
• Action: Reiterated Date: 10/30/25
• Date: Action: Reiterated 10/30/25

VETOQUINOL's overall stock score reflects strong financial performance and fair valuation. The company's solid profitability and efficient operations are key strengths. Technical analysis presents mixed signals, with potential downward pressure indicated by RSI. The absence of earnings call and corporate events data limits additional insights.

Positive Factors

Diversified product portfolio & global reach

A broad product mix across companion animals, livestock and aquaculture plus global distribution reduces reliance on a single market. This durable diversification smooths revenue cyclicality, enables cross‑selling, and supports balanced R&D allocation and long‑term resilience.

Negative Factors

Weak reported revenue trend

A reported ~-94.5% revenue change signals a material top‑line contraction that, if persistent, erodes scale economies and margin sustainability. Sustained revenue weakness would constrain R&D funding, limit reinvestment capacity and impair long‑term cash generation.

VETOQUINOL Business Overview & Revenue Model

Company Description

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammatio...

Read more

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammatio...

How the Company Makes Money

VETOQUINOL generates revenue primarily through the sale of its veterinary pharmaceuticals and health products. The company's revenue model is based on a diversified portfolio that includes prescription medications, over-the-counter products, and n...

Read more

VETOQUINOL generates revenue primarily through the sale of its veterinary pharmaceuticals and health products. The company's revenue model is based on a diversified portfolio that includes prescription medications, over-the-counter products, and n...

VETOQUINOL Financial Statement Overview

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	532.39M	539.20M	529.27M	539.78M	521.27M	427.47M
Gross Profit	184.09M	387.45M	291.38M	172.37M	167.37M	123.98M
EBITDA	108.53M	114.08M	112.33M	103.46M	116.86M	59.29M
Net Income	59.96M	58.69M	55.56M	47.99M	62.86M	19.22M
Balance Sheet
Total Assets	725.82M	744.13M	692.23M	651.85M	624.56M	646.09M
Cash, Cash Equivalents and Short-Term Investments	181.51M	206.33M	147.46M	93.71M	69.00M	129.44M
Total Debt	17.74M	21.12M	17.63M	17.42M	15.38M	124.86M
Total Liabilities	158.29M	168.20M	165.12M	167.19M	183.21M	274.26M
Stockholders Equity	567.45M	575.84M	527.01M	484.57M	441.26M	371.75M
Cash Flow
Free Cash Flow	55.76M	68.15M	70.38M	39.90M	56.76M	-53.45M
Operating Cash Flow	73.39M	85.83M	89.39M	62.39M	89.17M	92.01M
Investing Cash Flow	-21.14M	-15.65M	-18.88M	-21.52M	-33.45M	-145.14M
Financing Cash Flow	-27.15M	-16.03M	-15.50M	-16.06M	-120.31M	102.20M

VETOQUINOL Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 84.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:VETO, the sentiment is Negative. The current price of 84.4 is above the 20-day moving average (MA) of 78.97, above the 50-day MA of 83.07, and above the 200-day MA of 78.45, indicating a bearish trend. The MACD of -1.21 indicates Negative momentum. The RSI at 41.99 is Neutral, neither overbought nor oversold. The STOCH value of 58.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:VETO.

VETOQUINOL Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VETO	72 Outperform	€925.99M	17.31	10.49%	1.06%	-0.95%	27.67%
VIRP	68 Neutral	€2.97B	10.97	12.62%	0.41%	6.97%	-5.59%
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%